Global trial testing injection therapy for IgAN to report key results in 2027

Study still recruiting; drug aims to limit kidney inflammation, damage

Written by Michela Luciano, PhD |

A doctor holds up a magnifying glass to a holographic image of a person with both kidneys shown highlighted against the body.

An ongoing clinical trial involving adults with IgA nephropathy is investigating whether the therapy candidate agazisiran can help maintain kidney function. (Image from iStock)

Key results from a global clinical trial testing agazisiran, an injectable therapy aimed at limiting kidney inflammation and damage in people with immunoglobulin A nephropathy (IgAN) and other conditions, are expected next year, according to drug developer Adarx Pharmaceuticals.

The Phase 2 trial (NCT06989359) is still recruiting participants ages 18 and older at most of its active sites in the U.S. and in certain countries in Europe and Asia.

Launched in August 2025, the study is evaluating agazisiran’s safety and effectiveness in an estimated 85 adults with IgAN and other kidney diseases. The trial is now underway at 30-plus centers in more than a half-dozen countries.

The initial set of results, expected in mid-2027, will report on changes in urine protein levels, a marker of kidney function, after nine months of treatment, according to a press release from Adarx announcing the U.S.-based biotech company’s latest financial results and business updates.

Additional data, expected in the second half of the year, will provide data on whether a standard measure of kidney function remains stable after one year, per the developer.

“We have made significant progress across our pipeline” in the year to date, said Zhen Li, PhD, president and CEO of Adarx, noting the company’s plans to use new financing to advance its clinical-stage programs.

Recommended Reading
Red arrow-shaped sign with a white border and the words “FDA APPROVED” in large white letters against a gray background.

FDA approves first C5 inhibitor to reduce protein in urine for IgAN

IgAN is a rare kidney disorder in which abnormal IgA antibodies form clusters with other immune components and build up in the kidneys. These deposits can activate the complement system, a group of immune proteins that normally help the body fight infections.

When activated, the system sets off a chain reaction in which complement proteins activate one another to trigger inflammation. Over time, such inflammation can damage the kidneys, leading to excessive protein in the urine, known as proteinuria. In some people, this can result in a gradual decline in kidney function.

Experimental drug agazisiran works differently than Fabhalta

Agazisiran, formerly known as ADX-038, targets factor B, a complement protein involved in activating the alternative complement pathway — the main route by which the complement system is activated in IgAN.

Factor B is also targeted by Fabhalta (iptacopan), an approved oral treatment for IgAN that blocks the protein’s activity.

Agazisiran, however, works differently.

Administered by injection under the skin, the experimental treatment uses a technology known as small interfering RNA to break down the genetic instructions that liver cells use to make factor B. By reducing its production, agazisiran aims to suppress the alternative complement pathway, potentially limiting inflammation and kidney damage in IgAN.

Its effects are designed to last to last for several months, which could allow dosing every three or six months, rather than the twice-daily oral dosing required with Fabhalta.

In a Phase 1 clinical trial involving 41 healthy adults, agazisiran showed substantial, long-lasting reductions in factor B levels and alternative complement pathway activity.

Following a single injection at a dose of 6 mg/kg, alternative pathway activity was reduced by up to 99.9%, the data showed This suppression was sustained for six months, with pathway activity reduced by a mean of 98.3% and factor B levels by 93.5%.

No effects were observed on the activity of another complement pathway, called the classical pathway. This suggests that agazisiran can selectively suppress the alternative pathway while preserving activity in other parts of the complement system, which could help maintain the body’s ability to fight infections.

The data also showed that agazisiran was generally well tolerated, with no treatment-related serious adverse events or treatment discontinuations reported.

Recommended Reading
A scientist in a lab holds up a 3D model of the human urinary tract system, including the two kidneys.

Final trial data confirm effectiveness of now-approved IgAN treatment

Eligible participants with IgAN must have active kidney disease

The ongoing Phase 2 trial is designed to test the therapy in adults with one of three complement-related kidney diseases: IgAN, complement 3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).

To be eligible, participants with IgAN must have a diagnosis confirmed by kidney biopsy, evidence of active kidney disease, and sufficient kidney function. Eligible participants must also be receiving standard supportive care, when appropriate, and be willing to receive required vaccinations.

An estimated 25 IgAN patients will receive 300 mg of agazisiran every three months, while approximately 15 will receive 400 mg every six months. A third group of up to 15 people with C3G or IC-MPGN will receive 300 mg every three months, while another group involving 15 participants with any of the three kidney diseases will receive 400 mg every three months.

The study’s main goal is to assess agazisiran’s safety and tolerability over about three years by monitoring the frequency and severity of adverse events.

A key secondary goal is to measure changes in the urine protein-to-creatinine ratio (UPCR), which reflects how much protein is being lost through the urine. As an exploratory goal, the researchers will evaluate changes in estimated glomerular filtration rate (eGFR), a measure of how well the kidneys filter blood.

Adarx stated that it intends to explore additional dosing regimens in the IgAN trial.